Retrieved November 14, 2023, from https://www.globenewswire.com/news-release/2023/10/23/2764948/0/en/BioNTech-Presents-Positive-Phase-1-2-Data-Update-for-CAR-T-Cell-Therapy-Candidate-BNT211-in-Advanced-Solid-Tumors-at-ESMO-Congress-2023.html [8] Capstan Therapeutics to Present Preclinical ...
including 2-MC and 3-HP.b, LNP-encapsulated mRNAs encoding the human PCCA and PCCB subunits are delivered to target cells in the liver. After entry into the cytoplasm, the mRNAs are translated
At present, mRNA-based drugs are receiving increasing attention in cancer therapy, infectious disease prevention, protein replacement, and gene editing. Moreover, low costs and fast turnover rates in large-scale production confer great potential for the development of mRNA therapeutic platforms. This ...
Our lab has been committed to promoting mRNA-based therapeutics to become powerful and versatile tools to combat diseases, especially in gene therapy and immunotherapy.14We have developed diverse novel targeted delivery nanoparticles15and constructed receptor-binding domain (RBD)-encoding mRNA formulated i...
[252]. Subsequently, mRNA-based drugs have emerged as an attractive new therapeutic class, which is expected to revolutionize cancer treatment through different approaches, such as therapeutic vaccines, monoclonal antibodies, immunomodulatory drugs, and chimeric antigen receptor (CAR) cell therapy [22,...
“Our thesis is: amplified expression in specific, programmed target cells for long periods of time,” Becraft says. “That approach can be utilized for [immunotherapies like] CAR T-cell therapy, both in oncology and autoimmune conditions. There are also many diseases that require cell-type spe...
"Any risk of safety has to be really understood before we start. For therapy, (mRNA) needs to be administered on a chronic basis." The template for mRNA protein synthesis can lead to loss of some protein function, known as RNA toxicity. ...
Discover our groundbreaking cancer treatments and explore innovative approaches to harnessing myeloid cells for targeted cancer therapies.
& Yang, Z. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell. Mol. Immunol. 13, 3–10 (2016). Article CAS PubMed Google Scholar Rutkowski, A. J. et al. Widespread disruption of host transcription termination in HSV-1 infection. Nat. Commun. 6, ...
Thess, A. et al. Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol. Ther. 23, 1456–1464 (2015). Article CAS PubMed PubMed Central Google Scholar Parvathy, S. T., Udayasuriyan, V. & Bhadana, V. Codon usage bias...